Cancer stem cells: A review of potential clinical applications

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 8, 2013, Pages 1111-1116

  Podberezin, Mark ^a   Wen, Jianguo ^a   Chang, Chung Che ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL; CANCER STEM CELL; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; MINIMAL RESIDUAL DISEASE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS; NEOPLASTIC STEM CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879422194     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0494-RA     Document Type: Review

References (55)

1. D'Angelo RC, Wicha MS. Stem cells in normal development and cancer. Prog Mol Biol Transl Sci. 2010;95:113-158.
2. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15(9):494-501.
3. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol. 2011;223(2):147-161.
4. Cobaleda C, Gutiérrez-Cianca N, Pérez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood. 2000;95(3):1007-1013.
5. Passegué E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003;100(suppl 1):11842-11849. doi:10.1073/pnas.2034201100.
6. Conway AE, Lindgren A, Galic Z, et al. A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cellderived tumors. Stem Cells. 2009;27(1):18-28.
7. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150. doi:10.1146/annurev.pathol.1.110304.100224.
8. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006; 124(6):1111-1115.
9. Feng Y, Wen J, Mike P, et al. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells Dev. 2010;19(9): 1289-1296.
10. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8(5):486-498.
11. Purton LE, Scadden DT. Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell. 2007;1(3):263-270.
12. Greve B, Kelsch R, Spaniol K, Eich HT, Gotte M. Flow cytometry in cancer stem cell analysis and separation. Cytometry A. 2012;81(4):284-293. doi:10.1002/cyto.a.22022.
13. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011;10(9):1378-1384.
14. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 2006;312(19):3701-3710.
15. Mo SL, Li J, Loh YS, et al. Factors influencing the abundance of the side population in a human myeloma cell line. Bone Marrow Res. 2011;2011:524845.
16. Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31(2):73-99.
17. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117(17):4409-4419.
18. Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, Sorrentino BP. Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood. 2005;105(6):2571-2576.
19. Storms RW, Trujillo AP, Springer JB, et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A. 1999;96(16):9118-9123.
20. Hellsten R, Johansson M, Dahlman A, Sterner O, Bjartell A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS One. 2011;6(7): e22118. doi:10.1371/journal.pone.0022118.
21. Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood. 2006;107(5):2162-2169.
22. Yao T, Chen Q, Zhang B, Zhou H, Lin Z. The expression of ALDH1 in cervical carcinoma. Med Sci Monit. 2011;17(8):HY21-26.
23. Rahadiani N, Ikeda J, Mamat S, et al. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 2011;102(4):903-908.
24. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009;69(24):9245-9253.
25. Mauri FA, Pinato DJ, Trivedi P, Sharma R, Shiner RJ. Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion. Oncol Rep. 2012;28(2):647-653. doi:10.3892/or.2012.1818.
26. Lingala S, Cui YY, Chen X, et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010;89(1):27-35.
27. Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010;102(5):340-351.
28. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science. 2007;317(5836):337.
29. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123(9):1991- 2006.
30. Dave B, Chang J. Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia. 2009;14(1):79-82.
31. - cells in acute myeloid leukemia. Blood. 2012;119(15): 3571-3577. doi:10.1182/blood-2011-06-364182.
32. Foster AE, Okur FV, Biagi E, et al. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009; 8:106. doi:10.1186/1476-4598-8-106.
33. Foster AE, Okur FV, Biagi E, et al. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010;24(3):563-572.
34. Shafer JA, Cruz CR, Leen AM, et al. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010;51(5):870-880.
35. Gurchot C. The trophoblast theory of cancer (John Beard, 1857-1924) revisited. Oncology. 1975;31(5-6):310-333.
36. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615-625.
37. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol. 2010;6(5): 717-732.
38. Cuffel C, Rivals JP, Zaugg Y, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer. 2011;128(11):2625-2634.
39. Yanagawa N, Tamura G, Oizumi H, Endoh M, Motoyama T. MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer. Anticancer Res. 2011;31(1):171-175.
40. Kim SH, Lee S, Lee CH, et al. Expression of cancer-testis antigens MAGEA3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung. 2009;18(6)7:401-411.
41. Yoshida N, Abe H, Ohkuri T, et al. Expression of the MAGE-A4 and NYESO- 1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 2006;28(5):1089-1098.
42. Shigematsu Y, Hanagiri T, Shiota H, et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer. 2010;68(1):105-110.
43. Zhou JX, Li Y, Chen SX, Deng AM. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res. 2011;30:2.
44. Atanackovic D, Luetkens T, Hildebrandt Y, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res. 2009;15(4):1343-1352.
45. Andrade VC, Vettore AL, Felix RS, et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun. 2008;8:2.
46. Kono K, Mizukami Y, Daigo Y, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009;100(8): 1502-1509.
47. Quintarelli C, Dotti G, De Angelis B, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008;112(5):1876-1885.
48. Quintarelli C, Dotti G, Hasan ST, et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011;117(12):3353-3362.
49. + T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood. 2008;112(8):3362-3372.
50. + T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica. 2010;95(9):1572-1578.
51. Szmania S, Gnjatic S, Tricot G, et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007; 30(8):847-854.
52. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells. 2007;25(3):707-711.
53. Saldanha-Araujo F, Haddad R, Zanette DL, et al. Cancer/testis antigen expression on mesenchymal stem cells isolated from different tissues. Anticancer Res. 2010;30(12):5023-5027.
54. Cuffel C, Rivals JP, Zaugg Y, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer. 2011;128(11):2625-2634.
55. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 2005;65(18):8059-8064.